434
HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
a John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United States
b Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
c Amgen Inc., Thousand Oaks, United States
d Hôpital Claude Huriez, Lille, France
Read
847
Timeswas read the article
376
Total PDF
331
Total HTML
140
Total EPUB
| Year/Month | Html | Epub | Total | |
|---|---|---|---|---|
| 2022 January | 3 | 6 | 3 | 12 |
| 2021 December | 11 | 22 | 6 | 39 |
| 2021 November | 14 | 17 | 4 | 35 |
| 2021 October | 16 | 36 | 7 | 59 |
| 2021 September | 20 | 31 | 7 | 58 |
| 2021 August | 25 | 33 | 10 | 68 |
| 2021 July | 22 | 35 | 6 | 63 |
| 2021 June | 17 | 22 | 3 | 42 |
| 2021 May | 17 | 34 | 11 | 62 |
| 2021 April | 88 | 50 | 30 | 168 |
| 2021 March | 30 | 32 | 10 | 72 |
| 2021 February | 25 | 24 | 8 | 57 |
| 2021 January | 10 | 9 | 4 | 23 |
| 2020 December | 17 | 13 | 4 | 34 |
| 2020 November | 16 | 12 | 27 | 55 |
Show all
